VIR vs. DNA
VIR (Vir Biotechnology, Inc.) and DNA (Ginkgo Bioworks Holdings, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, VIR returned -24.65%/yr vs -54.05%/yr for DNA. Their 0.37 correlation means their historical movements had little consistent relationship.
Performance
VIR vs. DNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, VIR achieves a 43.62% return, which is significantly higher than DNA's -2.65% return.
VIR
- 1D
- -2.70%
- 1M
- -13.75%
- 6M
- 16.40%
- YTD
- 43.62%
- 1Y
- 72.17%
- 3Y*
- -15.28%
- 5Y*
- -24.65%
- 10Y*
- —
- ALL TIME*
- -8.75%
DNA
- 1D
- 0.00%
- 1M
- -22.21%
- 6M
- -9.81%
- YTD
- -2.65%
- 1Y
- -33.63%
- 3Y*
- -55.79%
- 5Y*
- -54.05%
- 10Y*
- —
- ALL TIME*
- -52.75%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $5.54M | $7.53M | $10.61M | |
| $13.61M | $14.70M | $17.41M |
VIR vs. DNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
VIR Vir Biotechnology, Inc. | 43.62% | -17.85% | -27.04% | -60.25% | -39.55% | -9.72% |
DNA Ginkgo Bioworks Holdings, Inc. | -2.65% | -15.38% | -85.47% | 0.00% | -79.66% | -21.68% |
Correlation
The correlation between VIR and DNA is 0.33, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.33 |
Correlation (3Y) Balances recent behavior with more history. | 0.38 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.38 |
Correlation (All Time) Calculated using the full available price history since Apr 19, 2021 | 0.37 |
Fundamentals
VIR:
$1.46B
DNA:
$528.48M
VIR:
-$3.12
DNA:
-$5.35
VIR:
18.75
DNA:
3.78
VIR:
1.57
DNA:
1.09
VIR:
$65.50M
DNA:
$121.84M
VIR:
$183.11M
DNA:
$99.27M
VIR:
-$448.10M
DNA:
-$218.90M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
VIR vs. DNA — Risk / Return Rank
VIR
DNA
VIR vs. DNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and Ginkgo Bioworks Holdings, Inc. (DNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VIR | DNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.44 | ||
| Sortino ratioReturn per unit of downside risk | +1.95 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 0.99 | +0.23 |
| Calmar ratioReturn relative to maximum drawdown | 2.78 | -0.58 | +3.36 |
| Martin ratioReturn relative to average drawdown | 6.37 | -0.92 | +7.28 |
Loading charts...
Drawdowns
VIR vs. DNA - Drawdown Comparison
The maximum VIR drawdown since its inception was -94.85%, roughly equal to the maximum DNA drawdown of -99.10%. Use the drawdown chart below to compare losses from any high point for VIR and DNA.
Loading charts...
Drawdown Indicators
| VIR | DNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.85% | -99.10% | +4.25% |
Max Drawdown (1Y)Largest decline over 1 year | -25.61% | -66.05% | +40.44% |
Max Drawdown (3Y)Largest decline over 3 years | -68.58% | -94.27% | +25.69% |
Max Drawdown (5Y)Largest decline over 5 years | -92.15% | -99.10% | +6.95% |
Current DrawdownCurrent decline from peak | -89.58% | -98.64% | +9.06% |
Average DrawdownAverage peak-to-trough decline | -68.14% | -80.34% | +12.20% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.16% | 42.00% | -30.84% |
Volatility
VIR vs. DNA - Volatility Comparison
The current volatility for Vir Biotechnology, Inc. (VIR) is 12.38%, while Ginkgo Bioworks Holdings, Inc. (DNA) has a volatility of 20.16%. This indicates that VIR experiences smaller price fluctuations and is considered to be less risky than DNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| VIR | DNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.38% | 20.16% | -7.78% |
Volatility (6M)Calculated over the trailing 6-month period | 45.20% | 71.47% | -26.27% |
Volatility (1Y)Calculated over the trailing 1-year period | 69.13% | 93.26% | -24.13% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 72.66% | 98.50% | -25.84% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 95.40% | 95.79% | -0.39% |
Dividends
VIR vs. DNA - Dividend Comparison
Neither VIR nor DNA has paid dividends to shareholders.
Financials
VIR vs. DNA - Financials Comparison
This section allows you to compare key financial metrics between Vir Biotechnology, Inc. and Ginkgo Bioworks Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
VIR and DNA have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
DNA has higher volatility (20.16%) compared to VIR (12.38%). In terms of maximum drawdown, VIR dropped -94.85% vs DNA's -99.10%.
VIR currently has the higher Sharpe Ratio (1.03 vs -0.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for VIR and DNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer